Zardo F, Antonini-Canterin F, Brieda M, Hrovatin E, Pavan D, Burelli C, Cervesato E, Nicolosi G L
Division of Cardiology, ARC, S. Maria degli Angeli Hospital, Pordenone, Italy.
Ital Heart J. 2001 Jul;2(7):513-8.
Calcium-lowering drugs seem to be able to reduce the recurrences of atrial fibrillation (AF) after cardioversion by preventing electrical remodeling of atrial cells. The aim of our study was to prospectively evaluate the efficacy of short-term verapamil therapy associated with propafenone or amiodarone in reducing recurrences of AF after low energy intracardiac cardioversion.
Eighty-two patients with chronic AF (mean duration 6.1 months, range 1-96 months) underwent low energy intracardiac cardioversion. Forty-one patients (Group A) were instructed to suspend antiarrhythmic therapy 48 hours before the procedure (only chronic amiodarone was allowed). The subsequent 41 patients (Group B), in addition to previous prescriptions, had to take verapamil (120 mg twice daily) for 3 days before low energy intracardiac cardioversion and for 7 days after cardioversion. A right atrium-coronary sinus or right atrium-left pulmonary artery electrode configuration was indifferently utilized. Propafenone (450-900 mg daily) or amiodarone (200 mg daily) was prescribed to all patients after cardioversion.
Sinus rhythm was acutely restored in 80 patients (97.6%): the mean number of shocks delivered was 2.3 (range 1-5); the mean energy required was 10.5 J (range 7.2-19.8 J). No statistically significant differences were found between the right atrium-coronary sinus vs right atrium-left pulmonary artery electrode configuration regarding the energy required and the number of shocks delivered. Group A and Group B showed the same number of AF recurrences at the first month of follow-up.
In our study, short-term verapamil treatment associated with propafenone or amiodarone seems to be useless for the prevention of recurrent AF after low energy intracardiac cardioversion.
降钙药物似乎能够通过防止心房细胞电重构来减少心脏复律后房颤(AF)的复发。我们研究的目的是前瞻性评估短期维拉帕米联合普罗帕酮或胺碘酮治疗在降低低能量心内复律后房颤复发方面的疗效。
82例慢性房颤患者(平均病程6.1个月,范围1 - 96个月)接受低能量心内复律。41例患者(A组)在手术前48小时被要求停用抗心律失常药物(仅允许使用慢性胺碘酮)。其余41例患者(B组)除先前的处方外,在低能量心内复律前3天和复律后7天必须服用维拉帕米(每日两次,每次120mg)。右心房 - 冠状窦或右心房 - 左肺动脉电极配置可随意使用。所有患者在复律后均服用普罗帕酮(每日450 - 900mg)或胺碘酮(每日200mg)。
80例患者(97.6%)急性恢复窦性心律:平均电击次数为2.3次(范围1 - 5次);平均所需能量为10.5J(范围7.2 - 19.8J)。在所需能量和电击次数方面,右心房 - 冠状窦与右心房 - 左肺动脉电极配置之间未发现统计学上的显著差异。A组和B组在随访的第一个月房颤复发次数相同。
在我们的研究中,短期维拉帕米联合普罗帕酮或胺碘酮治疗似乎对预防低能量心内复律后房颤复发无效。